Renaissance Technologies LLC Sells 20,198 Shares of Prestige Consumer Healthcare Inc. (NYSE:PBH)

Renaissance Technologies LLC trimmed its holdings in Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report) by 6.2% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 307,404 shares of the company's stock after selling 20,198 shares during the period. Renaissance Technologies LLC owned about 0.62% of Prestige Consumer Healthcare worth $24,005,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also recently made changes to their positions in PBH. Raymond James Financial Inc. bought a new stake in Prestige Consumer Healthcare during the 4th quarter valued at approximately $42,593,000. Norges Bank purchased a new stake in Prestige Consumer Healthcare during the 4th quarter valued at approximately $40,009,000. Boston Trust Walden Corp raised its position in shares of Prestige Consumer Healthcare by 43.5% during the fourth quarter. Boston Trust Walden Corp now owns 831,627 shares of the company's stock valued at $64,942,000 after buying an additional 252,089 shares during the last quarter. Natixis Advisors LLC lifted its holdings in shares of Prestige Consumer Healthcare by 1,335.1% in the fourth quarter. Natixis Advisors LLC now owns 209,246 shares of the company's stock worth $16,340,000 after buying an additional 194,665 shares in the last quarter. Finally, JPMorgan Chase & Co. boosted its position in shares of Prestige Consumer Healthcare by 44.5% during the fourth quarter. JPMorgan Chase & Co. now owns 393,474 shares of the company's stock worth $30,726,000 after acquiring an additional 121,219 shares during the last quarter. Institutional investors own 99.95% of the company's stock.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on PBH shares. Oppenheimer lifted their price target on shares of Prestige Consumer Healthcare from $87.00 to $93.00 and gave the company an "outperform" rating in a report on Thursday, February 13th. StockNews.com lowered Prestige Consumer Healthcare from a "buy" rating to a "hold" rating in a research report on Tuesday, April 8th. Raymond James upgraded Prestige Consumer Healthcare to a "moderate buy" rating in a research report on Thursday, December 19th. Canaccord Genuity Group raised their price target on Prestige Consumer Healthcare from $93.00 to $100.00 and gave the company a "buy" rating in a report on Friday, February 7th. Finally, Royal Bank of Canada lifted their price objective on Prestige Consumer Healthcare from $96.00 to $97.00 and gave the stock a "sector perform" rating in a research note on Friday, March 21st. Four investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat.com, Prestige Consumer Healthcare currently has an average rating of "Hold" and an average target price of $93.33.

Insider Buying and Selling at Prestige Consumer Healthcare

In related news, SVP Mary Beth Fritz sold 1,678 shares of Prestige Consumer Healthcare stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $90.00, for a total transaction of $151,020.00. Following the completion of the transaction, the senior vice president now directly owns 17,157 shares of the company's stock, valued at approximately $1,544,130. The trade was a 8.91 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 1.60% of the company's stock.

Prestige Consumer Healthcare Trading Up 0.4 %

Shares of NYSE:PBH traded up $0.30 during trading on Friday, reaching $80.10. The company's stock had a trading volume of 292,350 shares, compared to its average volume of 286,506. The firm's 50 day simple moving average is $84.27 and its two-hundred day simple moving average is $80.03. The company has a current ratio of 3.68, a quick ratio of 2.20 and a debt-to-equity ratio of 0.56. Prestige Consumer Healthcare Inc. has a 12 month low of $62.35 and a 12 month high of $90.04. The stock has a market capitalization of $3.97 billion, a PE ratio of 18.76, a price-to-earnings-growth ratio of 2.69 and a beta of 0.47.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last announced its earnings results on Thursday, February 6th. The company reported $1.22 EPS for the quarter, topping analysts' consensus estimates of $1.18 by $0.04. Prestige Consumer Healthcare had a return on equity of 12.36% and a net margin of 19.13%. On average, research analysts predict that Prestige Consumer Healthcare Inc. will post 4.5 EPS for the current fiscal year.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.